Clinical Trials

Abstract TBD

MC - Chippewa Falls Center

2655 CTY HWY I

CHIPPEWA FALLS, WI 54729

MC - Wausau Center

2727 PLAZA DRIVE

WAUSAU, WI 54401

MC - Wisconsin Rapids Center

220 24TH ST SOUTH

WISCONSIN RAPIDS, WI 54494

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9576 Highway 70

MINOCQUA, WI 54548

MMC - Rice Lake

1700 W STOUT ST

RICE LAKE, WI 54868

MMC - River Region at Stevens Point

4100 State Highway 66

Stevens Point, WI 54482

MMC - Weston

3400 Ministry Parkway

WESTON, WI 54476

This randomized phase III trial studies the best dose of apixaban and how well it works in preventing secondary cancer related blood clots in cancer patients who have completed anticoagulation therapy. Apixaban may stop the clotting of blood by blocking some of the enzymes needed for blood clotting.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This randomized clinical trial studies prophylactic colony stimulating factor management in patients with breast, colorectal or non-small cell lung cancer receiving chemotherapy and with risk of developing febrile neutropenia. Patients receiving chemotherapy may develop febrile neutropenia. Febrile neutropenia is a condition that involves fever and a low number of neutrophils (a type of white blood cell) in the blood. Febrile neutropenia increases the risk of infection. Colony stimulating factors are medications sometimes given to patients receiving chemotherapy to prevent febrile neutropenia. Colony stimulating factors are given to patients based on guidelines. Some clinics have an automated system that helps doctors decide when to prescribe them when there is a high risk of developing febrile neutropenia. Gathering information about the use of an automated system to prescribe prophylactic colony stimulating factor may help doctors use colony stimulating factor when it is needed.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

The purpose of this study is to assess the immune response against those strains and the safety of rMENB+OMVNZ vaccine when administered concomitantly with the 13-valent pneumococcal conjugate vaccine (PCV 13) and other US Advisory Committee on Immunization Practices (ACIP) recommended routine infant vaccines.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

zzzMarshfield Medical Center

611 Saint Joseph Ave

Marshfield, WI 54449

A cardinal feature of the rare disease Bardet-Biedl syndrome (BBS) is obesity. The purpose of this study is to examine physical activity and sleep behavior in individuals with BBS using a wrist-worn accelerometric device. The device will be worn for two week periods on repeated occasions to obtain information on activity and sleep behavior in individuals with BBS. Activity and sleep data will be correlated with health information currently collected in CRIBBS. Information gathered in this research is anticipated to promote understanding of energy metabolism and inform design of lifestyle interventions to treat obesity in the BBS population.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

zzzMarshfield Medical Center

611 Saint Joseph Ave

Marshfield, WI 54449

This partially randomized phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or crizotinib and standard therapy may work better in treating younger patients with neuroblastoma or ganglioneuroblastoma.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

To compare the effect of a supervised weight loss intervention plus health education materials versus health education materials alone upon invasive disease free survival (iDFS) in overweight (BMI 27-29.9 kg/m2) and obese (BMI =30kg/m2) women diagnosed with HER-2 negative, stage II and III breast cancer.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This phase II trial studies Trk inhibitor LOXO-101 in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with NTRK fusions that have spread to other places in the body and have come back or do not respond to treatment. Trk inhibitor LOXO-101 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This phase II trial studies how well pan-FGFR tyrosine kinase inhibitor JNJ-42756493 works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have spread to other places in the body and have come back or do not respond to treatment with FGFR mutations. Pan-FGFR tyrosine kinase inhibitor JNJ-42756493 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This phase II trial studies how well tazemetostat works in treating patients with solid tumors, non-hodgkin lymphoma, or histiocytic disorders that have spread to other places in the body and have come back or do not respond to treatment and have EZH2, SMARCB1, or SMARCA4 gene mutations. Tazemetostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449